ARCHIVES

ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication

This article is from The Cancer Letter archive.

Vol. 38 No. 07 | February 17, 2012

Download PDF Visit The Full Archive

Related Articles

Mason Asks For Better Technology Transfer In Cancer Prevention

October 30, 1992

Phase II Study Cohort Fails To Overcome Erlotinib Resistance

April 26, 2013

NCCS Networker Volume 8 Issue 3, Fall 1994

September 12, 1994

DCBDC Advisors Okay New Program In Breast Cancer

July 3, 1992

“Start Fighting” Says Former Rep. John Porter To Crowd of 12,000 at AACR Washington Rally

April 12, 2013

Conferees Set $1.991 Bil. NCI Budget, Ax Earmark For Breast Cancer, But Find $210 Mil. In Defense

October 9, 1992